198 related articles for article (PubMed ID: 30804903)
1. Oral Metallo-Beta-Lactamase Protects the Gut Microbiome From Carbapenem-Mediated Damage and Reduces Propagation of Antibiotic Resistance in Pigs.
Connelly S; Fanelli B; Hasan NA; Colwell RR; Kaleko M
Front Microbiol; 2019; 10():101. PubMed ID: 30804903
[TBL] [Abstract][Full Text] [Related]
2. Oral Beta-Lactamase Protects the Canine Gut Microbiome from Oral Amoxicillin-Mediated Damage.
Connelly S; Fanelli B; Hasan NA; Colwell RR; Kaleko M
Microorganisms; 2019 May; 7(5):. PubMed ID: 31137766
[TBL] [Abstract][Full Text] [Related]
3. SYN-004 (ribaxamase), an oral beta-lactamase, mitigates antibiotic-mediated dysbiosis in a porcine gut microbiome model.
Connelly S; Bristol JA; Hubert S; Subramanian P; Hasan NA; Colwell RR; Kaleko M
J Appl Microbiol; 2017 Jul; 123(1):66-79. PubMed ID: 28245091
[TBL] [Abstract][Full Text] [Related]
4. SYN-007, an Orally Administered Beta-Lactamase Enzyme, Protects the Gut Microbiome from Oral Amoxicillin/Clavulanate without Adversely Affecting Antibiotic Systemic Absorption in Dogs.
Connelly S; Fanelli B; Hasan NA; Colwell RR; Kaleko M
Microorganisms; 2020 Jan; 8(2):. PubMed ID: 31979034
[TBL] [Abstract][Full Text] [Related]
5. Identification, Characterization, and Formulation of a Novel Carbapenemase Intended to Prevent Antibiotic-Mediated Gut Dysbiosis.
Connelly S; Parsley T; Ge H; Kaleko M
Microorganisms; 2019 Jan; 7(1):. PubMed ID: 30654495
[TBL] [Abstract][Full Text] [Related]
6. Low dose oral beta-lactamase protects the gut microbiome from oral beta-lactam-mediated damage in dogs.
Connelly S; Fanelli B; Hasan NA; Colwell RR; Kaleko M
AIMS Public Health; 2019; 6(4):477-487. PubMed ID: 31909068
[TBL] [Abstract][Full Text] [Related]
7. Distinct consequences of amoxicillin and ertapenem exposure in the porcine gut microbiome.
Connelly S; Subramanian P; Hasan NA; Colwell RR; Kaleko M
Anaerobe; 2018 Oct; 53():82-93. PubMed ID: 29689301
[TBL] [Abstract][Full Text] [Related]
8. Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection.
Kaleko M; Bristol JA; Hubert S; Parsley T; Widmer G; Tzipori S; Subramanian P; Hasan N; Koski P; Kokai-Kun J; Sliman J; Jones A; Connelly S
Anaerobe; 2016 Oct; 41():58-67. PubMed ID: 27262694
[TBL] [Abstract][Full Text] [Related]
9. The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies.
Kokai-Kun JF; Roberts T; Coughlin O; Sicard E; Rufiange M; Fedorak R; Carter C; Adams MH; Longstreth J; Whalen H; Sliman J
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052855
[TBL] [Abstract][Full Text] [Related]
10. Ribaxamase, an Orally Administered β-Lactamase, Diminishes Changes to Acquired Antimicrobial Resistance of the Gut Resistome in Patients Treated with Ceftriaxone.
Kokai-Kun JF; Le C; Trout K; Cope JL; Ajami NJ; Degar AJ; Connelly S
Infect Drug Resist; 2020; 13():2521-2535. PubMed ID: 32801790
[TBL] [Abstract][Full Text] [Related]
11. Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial.
Kokai-Kun JF; Roberts T; Coughlin O; Le C; Whalen H; Stevenson R; Wacher VJ; Sliman J
Lancet Infect Dis; 2019 May; 19(5):487-496. PubMed ID: 30885591
[TBL] [Abstract][Full Text] [Related]
12. Nonclinical Safety Assessment of SYN-004: An Oral β-lactamase for the Protection of the Gut Microbiome From Disruption by Biliary-Excreted, Intravenously Administered Antibiotics.
Kokai-Kun JF; Bristol JA; Setser J; Schlosser M
Int J Toxicol; 2016 May; 35(3):309-16. PubMed ID: 26700136
[TBL] [Abstract][Full Text] [Related]
13. Formulation development of SYN-004 (ribaxamase) oral solid dosage form, a β-lactamase to prevent intravenous antibiotic-associated dysbiosis of the colon.
Bristol A; Hubert S; Hofmann F; Baer H
Int J Pharm; 2017 Dec; 534(1-2):25-34. PubMed ID: 28986322
[TBL] [Abstract][Full Text] [Related]
14. Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies.
Roberts T; Kokai-Kun JF; Coughlin O; Lopez BV; Whalen H; Bristol JA; Hubert S; Longstreth J; Lasseter K; Sliman J
Clin Drug Investig; 2016 Sep; 36(9):725-734. PubMed ID: 27283946
[TBL] [Abstract][Full Text] [Related]
15. Early-life gut microbiome modulation reduces the abundance of antibiotic-resistant bacteria.
Casaburi G; Duar RM; Vance DP; Mitchell R; Contreras L; Frese SA; Smilowitz JT; Underwood MA
Antimicrob Resist Infect Control; 2019; 8():131. PubMed ID: 31423298
[TBL] [Abstract][Full Text] [Related]
16. Same Exposure but Two Radically Different Responses to Antibiotics: Resilience of the Salivary Microbiome versus Long-Term Microbial Shifts in Feces.
Zaura E; Brandt BW; Teixeira de Mattos MJ; Buijs MJ; Caspers MP; Rashid MU; Weintraub A; Nord CE; Savell A; Hu Y; Coates AR; Hubank M; Spratt DA; Wilson M; Keijser BJ; Crielaard W
mBio; 2015 Nov; 6(6):e01693-15. PubMed ID: 26556275
[TBL] [Abstract][Full Text] [Related]
17. A Clinical Study Provides the First Direct Evidence That Interindividual Variations in Fecal β-Lactamase Activity Affect the Gut Mycobiota Dynamics in Response to β-Lactam Antibiotics.
Delavy M; Burdet C; Sertour N; Devente S; Docquier JD; Grall N; Volant S; Ghozlane A; Duval X; Mentré F; d'Enfert C; Bougnoux ME;
mBio; 2022 Dec; 13(6):e0288022. PubMed ID: 36448778
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal assessment of antibiotic resistance gene profiles in gut microbiomes of infants at risk of eczema.
Loo EXL; Zain A; Yap GC; Purbojati RW; Drautz-Moses DI; Koh YQ; Chong YS; Tan KH; Gluckman PD; Yap F; Eriksson JG; Tham E; Shek LP; Kjelleberg S; Schuster SC; Banerjee R; Lee BW
BMC Infect Dis; 2020 Apr; 20(1):312. PubMed ID: 32345218
[TBL] [Abstract][Full Text] [Related]
19. An engineered live biotherapeutic for the prevention of antibiotic-induced dysbiosis.
Cubillos-Ruiz A; Alcantar MA; Donghia NM; Cárdenas P; Avila-Pacheco J; Collins JJ
Nat Biomed Eng; 2022 Jul; 6(7):910-921. PubMed ID: 35411114
[TBL] [Abstract][Full Text] [Related]
20. Machine Learning Leveraging Genomes from Metagenomes Identifies Influential Antibiotic Resistance Genes in the Infant Gut Microbiome.
Rahman SF; Olm MR; Morowitz MJ; Banfield JF
mSystems; 2018; 3(1):. PubMed ID: 29359195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
